CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 342 enrolled
Drug / intervention
Symptom-based adjustment +2 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00495157
NCT00495157Phase 3Completed
CompareCT.gov

Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT)

Milton S. Hershey Medical Center·interventional·Posted Jul 2, 2007·Updated Apr 11, 2013

In Brief

A Phase 3 clinical trial evaluating Symptom-based adjustment, Biomarker-based adjustment, and 1 other intervention for Asthma. Completed, enrolled 342 participants across 10 sites.

Detailed Summary

Asthma can be effectively controlled using inhaled corticosteroid medication. Treatment with inhaled corticosteroids often requires periodic adjustments to medication dosing and frequency levels. This study examines whether it is more beneficial to adjust corticosteroid treatment based on asthma symptoms and/or biomarkers of lung function versus standard medical guidelines.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2, 2007
Enrollment StartJun 1, 2007
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 19 years ago

Interventions

Symptom-based adjustmentbehavioral

Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)

Biomarker-based adjustmentbehavioral

Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)

Guideline-based adjustmentbehavioral

Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)